



Octagam 10%® (immune globulin intravenous [human]) – New indication

- On July 15, 2021, the FDA approved Octapharma's Octagam 10% (immune globulin intravenous [human]), for the treatment of dermatomyositis in adults.
- Octagam 10% is also approved for the treatment of chronic immune thrombocytopenic purpura (ITP) to rapidly raise platelet counts to control or prevent bleeding in adults.
- The approval of Octagam 10% for the new indication was based on a double-blinded, randomized, placebo-controlled study in 95 adults with dermatomyositis. The primary endpoint was the proportion of responders at week 16. A responder was defined as a subject with a minimal improvement of ≥ 20 points on the Total Improvement Score (TIS).
 - Response was achieved in 78.7% of patients treated with Octagam 10% vs. 43.8% with placebo (difference of 35.0, 95% CI: 16.7, 53.2; $p = 0.0008$).
- Octagam 10% has boxed warnings for thrombosis, renal dysfunction, and acute renal failure.
- The most common adverse reactions ($> 5\%$) with Octagam 10% use for dermatomyositis were headache, fever, nausea, vomiting, increased blood pressure, chills, musculoskeletal pain, increased heart rate, dyspnea, and infusions site reactions.
- The recommended dose of Octagam 10% for the treatment of dermatomyositis is 2 g/kg divided in equal doses given over 2-5 consecutive days every 4 weeks
 - Refer to the Octagam 10% drug label for dosing for chronic ITP.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](https://www.optum.com).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2021 Optum, Inc. All rights reserved.